anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A compound non-bonding to heparin, inert to activation with heparin, inert to fibroblast cell, specifically proliferating vascular endothelial cell, having an isoelectric point of 4.6 and a mol. wt. of 44,000-46,000 and composed of a simple peptide chain having an amino acid composition of Asx, Thr, Ser, Glx, Pro, Gly, Ala, Cys, Val, Met, Ile, Leu, Phe, His, Lys and Arg. USE:Agent for promoting healing of wound and preventive for arteriosclerosis. PREPARATION:For example, fresh human blood is treated by cation exchange chromatography and the non-adsorbed fraction is treated by anion exchange chromatography. The adsorbed fraction is eluted and precipitated with ammonium sulfate in neutral state. The precipitate is reduced and purified e.g. by anion exchange chromatography, hydroxyapatite chromatography and gel chromatography to obtain the objective vascular endothelial cell growth factor.
The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
Participants will have 8 weeks to receive 6 therapy sessions. Content is dynamically driven by an animated therapist who guides the user through the program.
The invention discloses a stomach invigoration healthcare product and a preparation method thereof. The stomach invigoration healthcare product is characterized by consisting of dandelions, processed rheum officinale, swimming crab chitosan, calcined oyster shells, fingered citron, fructus amomi volatile oil and medicinal auxiliary materials. In the prescription, the swimming crab chitosan and the calcined oyster shells have functions of inhibiting gastric acid secretion, protecting gastric mucosa and suppressing bacteria; the dandelion and the processed rheum officinale have the functions of clearing heat, removing toxin and preventing bacteria; the fructus amomi and the fingered citron have the functions of tonifying the spleen and stimulating appetite, regulating qi and alleviating pain as well as promoting digestion. The prescription is based on the idea of 'treatment based on syndrome differentiation'of the traditional Chinese medicine, medicines are taken reasonably, and thus the effects of treating both symptoms and root causes can be achieved. Experiment tests demonstrate the scientificity and the effectiveness of the prescription, and the prescription can be developed into stomach invigoration healthcare products or medicines with pharmacologic actions of protecting gastric mucosa, preventing gastric ulcer and promoting digestion. The stomach invigoration healthcare product has the advantages of being simple in component, short in treatment course, rapid in effect taking, good in treatment effect and free of toxic or side effect, and different from conventional stomach medicines, the stomach invigoration healthcare product is a formula and a product which is very good in effect on gastric ulcer and dyspepsia.
FIELD: genetic and protein engineering, microbiological and medicinal industry. SUBSTANCE: invention relates to preparing recombinant plasmid DNA pKHBc-33 containing gene of hepatitis B virus core antigen (HBcAg) with the main neutralizing epitope of hepatitis B virus surface antigen (137-147) (HBsAg) exhibited on its surface and the corresponding strain-producer. Plasmid has also structural members that are necessary for hybrid protein expression providing in strain-producer cells. For preparing strain-producer competent cells of bacterium Escherichia coli JM103 are transformed with plasmid pKHBc-33. Obtained strain E. coli JM103/pKHBc-33 provides the induced synthesis of HBcAg-HBsAg (137-147) at expression level 5% of total cell protein. EFFECT: recombinant plasmid preparing. 2 cl, 3 dwg
Experimental (MSPE group). The experimental group received the Mindful Sport Performance Enhancement programme (MSPE), with some changes and adaptations taking into account the characteristics and needs of the Para-athletes and the overall aim of the study. Such as reducing the session time (2h), including staff and support material, extending the pre-session time (35-40 min), and incorporating the dynamics of emotions and Mindful Yoga into the floor of the MBSR programme \[2\].
Patients will receive sorafenib at a dose of 400 mg twice daily after 2 weeks of hepatic resection. At the same time, TACE is performed two to four weeks after hepatic resection.
Patient will receive institutional standard bowel protocol. Beginning on post-operative day one either miralx,docusate sodium or senna, on a weight-based dose. If no bowel movement in 72 hours, either oral bisacodyl or magnesium hydroxide, on a weight-based dosing, will be added.
A person who has or is suspected of having keratoconus. Will have either or both Artemis-2 exam and OCT exam.
Phase 2, open-label, non-randomized, single-arm, drug treatment trial. 10 subjects will be studied. Treatment duration of 6 months with 3 months off drug follow-up and optional extension phase.
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of trospium chloride was evaluated in controlled clinical trials in a total of 2975 patients, who were treated with trospium chloride (N=1673), placebo (N=1056) or active control medications (N=246). Of this total, 1181 patients participated in two, 12-week, U.S., efficacy and safety studies and a 9-month open-label extension. Of this total, 591 patients received trospium chloride tablets 20 mg twice daily. In all controlled trials combined, 232 and 208 patients received treatment with trospium chloride for at least 24 and 52 weeks, respectively.

In all placebo-controlled trials combined, the incidence of serious adverse events was 2.9% among patients receiving trospium chloride tablets 20 mg twice daily and 1.5% among patients receiving placebo. Table 1 lists adverse reactions from the combined 12-week U.S. safety and efficacy trials were reported by at least 1% of patients, and were reported more frequently in the trospium chloride group than in the placebo group.

The two most common adverse reactions reported by patients receiving trospium chloride tablets 20 mg twice daily were dry mouth and constipation. The single most frequently reported adverse reaction for trospium chloride tablets, dry mouth, occurred in 20.1% of trospium chloride treated patients and 5.8% of patients receiving placebo. In the two U.S. studies, dry mouth led to discontinuation in 1.9% of patients treated with trospium chloride tablets 20 mg twice daily. For the patients who reported dry mouth, most had their first occurrence of the event within the first month of treatment.

Table 1. Incidence (%) of adverse reactions with trospium chloride, reported in greater than or equal to 1% of all patients treated with trospium chloride tablets and more frequent with trospium chloride tablets (20 mg twice daily) than placebo in Studies 1 and 2 combined

Other adverse reactions from the U.S., placebo-controlled trials, occurring in greater than or equal to 0.5% and less than 1.0% of patients treated with trospium chloride, and more common with trospium chloride than placebo are: tachycardia, vision blurred, abdominal distension, vomiting, dysgeusia, dry throat, and dry skin.

During controlled clinical studies, one adverse reaction of angioneurotic edema was reported.
This is a randomized study comparing the efficacy of inducing weight loss of two treatment arms all based on the Colorado Diet. Subjects will be randomly assigned to one of two study arms and instructed to follow the Colorado Diet by participating in weekly State of Slim group classes. Subjects will be followed in the study for one year. The Colorado Diet consists of 3 phases: phase 1 (week 1-2), phase 2 (weeks 3 - 8), and phase 3 (weeks 9 - 16). The maintenance phase lasts from months 5 - 12. Body weight will be monitored at each study visit and body composition will be determined using DXA. Blood lipid and lipoprotein concentrations, health \& wellness questionnaires, and fitness measures will also be assessed throughout the study.
According to the inclusion and exclusion criteria, 34 female patients with OAB were enrolled in the study. The patients were randomly divided into two groups, with 17 individuals in each group. Patients with odd case numbers were assigned to the Oral Solifenacin group, while those with even case numbers were assigned to the TTNS group.

Prior to treatment, the sociodemographic characteristics, birth history, and past treatment information of all participants were recorded. Basic urogynecological evaluation, pelvic floor ultrasound, and urine culture were performed. To assess symptoms and quality of life, the Overactive Bladder Assessment Form (OAB-V8), Incontinence Quality of Life Scale (I-QQL), Incontinence Impact Questionnaire (IIQ-7), Urogenital Distress Inventory (UDI-6), and a three-day bladder diary were used. After 6 weeks of treatment, all evaluations were repeated. The treatment regimen consisted of once-daily oral solifenacin for the medication group and 2 sessions per week, 30 minutes per session, for 12 sessions using the Urostim-2 device for the TTNS group. The stimulation intensity was increased until a motor or sensory response was obtained, and the threshold value was determined. The entire TTNS procedure was performed under the supervision of an expert physician at the Urogynecology Outpatient Clinic of Ege University Hospital. Statistical analysis was conducted using SPSS 20.0.
INTRODUCTION: Statins have demonstrated chondroprotective effects by reducing inflammation and mitigating extracellular matrix degradation. However, statins are also reported to be cytotoxic to several types of cells. Early-onset osteoarthritis (OA) is characterized by synovial inflammation, which adversely affects hyaluronan (HA) production in fibroblast-like synoviocytes (FLSs). Nevertheless, the precise effects of statins on the synovium remain unclear.
METHODS: This study investigated the impact of lovastatin on human FLSs, and HA secretion-related genes, signaling pathways, and production were evaluated.
RESULTS: The findings revealed that high doses of lovastatin (20 or 40 μM) decreased FLS viability and increased cell death. FLS proliferation ceased when cultured in a medium containing 5 or 10 μM lovastatin. mRNA expression analysis demonstrated that lovastatin (5 and 10 μM) upregulated the gene level of hyaluronan synthase 1 (HAS1), HAS2, and proteoglycan 4 (PRG4), but not HAS3. While the expression of multidrug resistance-associated protein 5 transporter gene remained unaffected, both inward-rectifying potassium channel and acid-sensing ion channel 3 were upregulated. Western blot further confirmed that lovastatin increased the production of HAS1 and PRG4, and activated the PKC-α, ERK1/2, and p38-MAPK signaling pathways. Additionally, lovastatin elevated intracellular cAMP levels and HA production in FLSs.
CONCLUSION: Lovastatin impairs cellular proliferation but enhances HA production in human FLSs.
<P>PROBLEM TO BE SOLVED: To provide a compound useful for inducing cytokine biosynthesis in animal bodies.  <P>SOLUTION: The compound is 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5] naphthyridin-4-amine or a pharmaceutically acceptable salt thereof. The pharmaceutical composition containing a pharmaceutically effective amount of the compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier is provided. The effective amount of the compound or a pharmaceutically acceptable salt thereof and for inducing the biosynthesis of animal cytokine is administered to animals. The effective amount of the compound or a pharmaceutically acceptable salt thereof and for treating animal virus infection is administered to an animal.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Coordinated by the ICL who co-ordinates key activities at each site to address the two core components of the Intervention. Component 1 activities include: (a) person-centred assessment of residents, focussing on their physical, psychological, emotional and social needs, (b) meetings of the core care team (General practitioner, care home nurse and/or manager and ICL) and (c) meetings of the wider multidisciplinary care teams (including care home staff, ICL, and external healthcare professionals such as geriatrician, palliative care, mental health etc). Activities to facilitate component 2 include: (d) staff training sessions, education and support for staff and family carers. Training sessions are run by the ICL and logistics of training is planned at core meetings.
Abstract of the Disclosure A dialkyl quaternary ammonium compound fall-ing within the formula   An-wherein R1 and R2 are the same or different straight chain alkyl radicals CnH2n+1 wherein n is predominant-ly at least 12, and particularly where n equals predomi-nantly 12-16, unexpectedly prevents Ext. D & C Violet No.  2 dye from staining skin while providing better deposition of the Ext. D & C Violet No. 2 onto human hair and wool to decrease or eliminate hair and wool yellowing.  These fatty radicals R1 and R2 are gener-ally derived from coconut oil, lauric acid, myristic acid, or palmitic acid and An- is any anion, parti-cularly the halogen ions and particularly the chloride ion.
Within the last years, protein analyses of Aβ-species in the cerebrospinal fluid (CSF) and amyloid-imaging using F18-based PET-tracers have become a part of the diagnostic repertoire in specialized memory clinics allowing a neurobiological, biomarker-based validation of Alzheimer´s disease (AD) diagnosis. This has led to a substantial increase in the specificity of the diagnostic procedure. However, the problem remains that the diverse factors, which influence disease progression are largely unknown, while tools for diagnosis have improved substantially.

We will identify patients for participation in a long-term clinical follow up study. Biomaterial (CSF, blood) will be obtained at baseline and subjected to a detailed protein analysis. In a subset of patients, a lumbar puncture will be repeated to compare baseline and follow up CSF. Within this study, a panel of proteins, comprising Aβ- and Tau-species as well as inflammation, glial and synaptic markers, potentially involved in disease progression will be measured in biomaterial from baseline and from follow up assessment. Clinical data will be correlated with the panel of disease and progression markers.
A number of modalities for preventing HCC recurrence after resection have been proposed and analyzed. Both preoperative and adjuvant transcatheter arterial chemoembolization (TACE) were found to be unable to reduce the risk of postoperative recurrence significantly, or confer a survival advantage. Vitamin K (VK) is a fat-soluble vitamin that regulates clotting factor production by acting as a coenzyme for a VK dependent carboxylase that catalyzes carboxylation of glutamic acid residues into gamma-carboxyglutamic acid. The findings in vitro have indicated that VK2 has an antiproliferative effects against hepatoma cell lines, but its efficacy in suppressing HCC recurrence was not confirmed in human studies. Interferon has a variety of biologic properties, including antiviral, immunomodulatory, antiproliferative, antiangiogenic and tumoricidal effects. It is reported that interferon is effective in preventing the development of HCC recurrence after its curative treatment in HCV-related cirrhosis. However, interferon treatment also has side-effects, including flu-like symptoms, fatigue, neutropenia, thrombocytopenia, depression, bone marrow suppression, and unmasking or exacerbation of autoimmune illnesses, which lead either to treatment disruption or dose modification. Polyprenoic acid, an acyclic retinoid, reportedly is effective in prevention of second primary hepatomas, but long-term safety and efficacy data are lacking.

Thalidomide possesses immunomodulatory,anti-inflammatory, and antiangiogenic properties.It has successfully been applied for the treatment of various malignancies including HCC.To investigated whether postoperative adjuvant therapy with Thalidomide could inhibite the recurrence of HCC after radical resection,we planed to conduct this clinical trial.
The pattern of adverse effects seen with dicylomine is mostly related to its pharmacological actions at muscarinic receptors [see Error! Hyperlink reference not valid. (Error! Hyperlink reference not valid.)]. They are a consequence of the inhibitory effect on muscarinic receptors within the autonomic nervous system. These effects are dose-related and are usually reversible when treatment is discontinued.

The most serious adverse reactions reported with dicyclomine hydrochloride include cardiovascular and central nervous system symptoms [see Error! Hyperlink reference not valid. (5.2, 5.3)].
Patients with locally advanced or recurrent soft tissue sarcoma will receive Sunitinib and irradiation as neoadjuvant treatment. Restaging and tumor resection will be performed 6 weeks after completion of sunitinib and irradiation.
PURPOSE: A picture naming test is presented that reveals impairment to specific mechanisms involved in the naming process, using accuracy scores on curated item sets. A series of psychometric validation experiments are reported.
METHOD: Using a computational model that enables estimation of item difficulty at the lexical and sublexical stages of word retrieval, two complimentary sets of items were constructed that challenge the respective psycholinguistic levels of representation. The difference in accuracy between these item sets yields the relative linguistic impairment (RLI) score. In a cohort of 91 people with chronic left-hemisphere stroke who enrolled in a clinical trial for anomia, we assessed psychometric properties of the RLI score and then used the new scale to make predictions about other language behaviors, lesion distributions, and functional activation during naming.
RESULTS: RLI scores had adequate psychometric properties for clinical significance. RLI scores contained predictive information about spontaneous speech fluency, over and above accuracy. A dissociation was observed between performance on the RLI item sets and performance on the subtests of an independent language battery. Sublexical RLI was significantly associated with apraxia of speech and with lesions encompassing perisylvian regions, while lexical RLI was associated with lesions to deep white matter. The RLI construct was reflected in functional brain activity during naming, independent of overall accuracy, with a respective shift of activation between dorsal and ventral networks responsible for different aspects of word retrieval.
CONCLUSION: The RLI assessment satisfies the psychometric requirements to serve as a useful clinical measure.
Herein, PC12 cells were applied to detect the impact of progesterone under oxygen glucose deprivation/reperfusion (OGD/R) stimulation. The cell proliferation of PC12 cells was evaluated by cell counting kit-8 assay, and the concentrations of MDA, ROS and SOD were examined by their corresponding Enzyme Linked Immunosorbent Assay kits. The invasion and migration properties of PC12 cells were evaluated by transwell and wound healing assays, respectively. The expression patterns of related genes were evaluated by western blot and qPCR. Under OGD/R stimulation, progesterone treatment could elevate the viability of PC12 cells, reduce the levels of MDA and ROS, and elevate the concentration of SOD. Moreover, progesterone treatment could strengthen the invasion and migration abilities of PC12 cells under OGD/R condition, as well as decrease the apoptosis and inflammation. FABP5 expression was significantly increased in PC12 cells under OGD/R stimulation, which was reversed after progesterone stimulation. Under OGD/R stimulation, the protective effects of progesterone on PC12 cells were strengthened after si-FABP5 treatment. The protein levels of TLR4, p-P65 NF-κB, and P65 NF-κB in OGD/R-induced PC12 cells were increased, which were inhibited after progesterone treatment. Progesterone exerted protective effects on PC12 cells by targeting FABP5 under OGD/R stimulation.
<P>PROBLEM TO BE SOLVED: To provide a drug that is harmless to human bodies and is capable of obtaining AMPK- and GLUT4-activating effects without inducing any adverse effects, and a pharmaceutical drug, food and drink expected to be effective in improving diabetes, obesity, etc. due to the AMPK- and GLUT4-activating effects.  <P>SOLUTION: An AMPK activator comprises dimeric to octameric proanthocyanidin as an active ingredient. A GLUT4 activator comprises proanthocyanidin as an active ingredient. An antidiabetic agent, an anti-obesity agent, a visceral fat reducing agent or a visceral fat accumulation inhibitor each comprises these drugs. The food and drink contain these medical drugs.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Pancreatic cancer participants will be treated with QLS31905 in combination with nab-paclitaxel and gemcitabine for part A of the study to establish the recommended dose of QLS31905 for part B. In part B, the participants will be treated with QLS31905 at a dose determined by the part A of the study in combination with nab-paclitaxel and gemcitabine.
Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week there after while receiving usual and customary care, but actual frequency of visits will be determined by the treating physician. Usual and customary care, which can include any advanced therapeutics.
OBJECTIVES: To determine the effectiveness and safety of Hemopatch® as a primary dural sealant in preventing CSF leakage following cranial surgery. Cerebrospinal fluid (CSF) leaks occur in cranial operations and are associated with significant patient burden and expense. The use of Hemopatch® as a dural sealant in cranial neurosurgical procedures is described and analyzed in this study.
METHODS: Data were retrospectively collected from all patients who underwent a craniotomy for various neurosurgical indications where Hemopatch® was used as the primary dural sealant between June 2017 and June 2022. Infection and CSF leak were the main indicators evaluated after surgery.
RESULTS: A total of 119 consecutive patients met our inclusion criteria. The median was age 41.5 years, and 52.5% were female. The mean follow-up period was 2.3 years (7 months to 6 years). There were 110 (92.44%) supratentorial and 9 (7.56%) infratentorial craniotomies. Postoperative CSF leak was reported in 2 patients (1.68%), one in each cohort. Postoperative infection occurred in one patient (0.84%).
CONCLUSION: The results suggest that using Hemopatch® as a dural sealant in cranial surgery is effective and safe. After supra-/infratentorial craniotomies, the rate of postoperative adverse events in our sample was within the range of known surgical revision rates. Future randomized clinical studies are required to confirm our encouraging findings.
Nutrient feed compsn. for cattle and swine comprises polycyclic ether antibiotic of formula (I) or salt, where R and R1 are each H or Me. (I) may be obtd. e.g. by submerged aerobic fermentation of Actinomadura Sp. ATCC 39697. (I) are effective in controlling coccidiosis, euteritis, swine dysentery and theileriosis, as well as being effective in promoting growth and increasing efficiency of feed utilisation in swine and ruminants.